Effcacy of combination of immunotherapy and chemotherapy as frst-line treatment for disseminated non-small cell lung cancer: a case report
https://doi.org/10.21294/1814-4861-2026-25-1-186-191
Abstract
Background. Lung cancer is one of the most common cancers worldwide. Most newly diagnosed lung cancer patients present with distant metastases.
Objective: to demonstrate a successful clinical case showing longterm overall and relapse-free survival rates in a patient with disseminated non-small cell lung cancer treated with a combination of immunotherapy and chemotherapy.
Case presentation. A 72-year-old patient diagnosed with stage IV (T1bN0M1b) non-small cell lung asenocarcinoma of the right upper lobe achieved long-term disease stabilization using a combination of atezolizumab, bevacizumab and chemotherapy. The overall and progression-free survival was 38 months with a favorable safety profle.
Conclusion. Despite current drug therapy options, the treatment of metastatic NSCLC remains challenging. This case report demonstrates the effcacy of atezolizumab in combination with bevacizumab and chemotherapy in patients with metastatic, untreated EGFR- and ALK -negative NSCLC negative for programmed cell death ligand 1 (PD-L1).
About the Authors
G. K. Isaeva
South Ural State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Galiya K. Isaeva, MD, Assistant, Department of Oncology, Radiation Diagnostics and Radiation Therapy
64, Vorovskogo St., Chelyabinsk, 454141
M. M. Sarycheva
South Ural State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Marina M. Sarycheva, MD, DSc, Associate Professor, Department of Oncology, Radiation Diagnostics and Radiation Therapy
64, Vorovskogo St., Chelyabinsk, 454141
A. V. Vazhenin
South Ural State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Andrey V. Vazhenin, MD, DSc, Professor, Academician of the Russian Academy of Sciences, Head of the Department of Oncology, Radiation Diagnostics and Radiation Therapy
64, Vorovskogo St., Chelyabinsk, 454141
A. V. Dubinina
South Ural State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Anna V. Dubinina, MD, Resident, Department of Oncology, Radiation Diagnostics and Radiation Therapy
64, Vorovskogo St., Chelyabinsk, 454141
K. M. Sheveleva
South Ural State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Kristina M. Sheveleva, MD, Resident, Department of Oncology, Radiation Diagnostics and Radiation Therapy
64, Vorovskogo St., Chelyabinsk, 454141
I. V. Makruta
South Ural State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Irina V. Makruta, MD, Resident, Department of Oncology, Radiation Diagnostics and Radiation Therapy
64, Vorovskogo St., Chelyabinsk, 454141
References
1. Cancer TODAY. IARC Publications, International Agency for Research on Cancer. Data version: Globocan 2022 (version 1.1). [Internet]. [cited 06.11.2025]. URL: https://gco.iarc.who.int/today.
2. Cancer care for the population of Russia in 2023. Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow, 2024. 262 p. (in Russian). ISBN: 978-5-85502-297-1.
3. Lung cancer: сlinical recommendations of the Ministry of Health of the Russian Federation. 2025. (in Russian). [Internet]. [cited 25.02.2026]. URL: https://cr.minzdrav.gov.ru/view-cr/30_5.
4. Mok T.S.K., Wu Y.L., Kudaba I., Kowalski D.M., Cho B.C., Turna H.Z., Castro G.Jr., Srimuninnimit V., Laktionov K.K., Bondarenko I., Kubota K., Lubiniecki G.M., Zhang J., Kush D., Lopes G.; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183): 1819–30. doi: 10.1016/S0140-6736-(18)32409-7.
5. Socinski M.A., Nishio M., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodríguez-Abreu D., Moro-Sibilot D., Thomas C.A., Barlesi F., Finley G., Kong S., Lee A., Coleman S., Zou W., McCleland M., Shankar G., Reck M. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in FirstLine Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021; 16(11): 1909–24. doi: 10.1016/j.jtho.2021.07.009.
6. West H.J., McCleland M., Cappuzzo F., Reck M., Mok T.S., Jotte R.M., Nishio M., Kim E., Morris S., Zou W., Shames D., Das Thakur M., Shankar G., Socinski M.A. Clinical efcacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. J Immunother Cancer. 2022; 10(2): e003027. doi: 10.1136/jitc-2021-003027.
7. Lu T., Hamidi H., Socinski M.A., Reck M., Cappuzzo F., Barlesi F., Jotte R.M., Müller S., Qamra A., Amitai A., Guan X., Fuentes E., Koeppen H., Giltnane J.M., Shames D.S., Ballinger M., He M.X., Wang Y., Srivastava M.K., Nabet B.Y. Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations. Nat Commun. 2025; 17(1): 122. doi: 10.1038/s41467-025-66803-8.
8. Brahmer J.R., Lee J.S., Ciuleanu T.E., Bernabe Caro R., Nishio M., Urban L., Audigier-Valette C., Lupinacci L., Sangha R., Pluzanski A., Burgers J., Mahave M., Ahmed S., Schoenfeld A.J., Paz-Ares L.G., Reck M., Borghaei H., O’Byrne K.J., Gupta R.G., Bushong J., Li L., Blum S.I., Eccles L.J., Ramalingam S.S. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol. 2023; 41(6): 1200–12. doi: 10.1200/JCO.22.01503.
9. Zhao H., Huang S., Wu J., Lu Y., Zou Y., Zeng H., Li C., Wang J., Zhang X., Duan S., Liang W. Efcacy and safety of frst-line PD-1/PDL1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis. Front Immunol. 2025; 16: 1515027. doi: 10.3389/fmmu.2025.1515027.
10. Carbone D.P., Ciuleanu T.E., Cobo M., Schenker M., Zurawski B., Menezes J., Richardet E., Felip E., Cheng Y., Juan-Vidal O., Alexandru A., Mizutani H., Reinmuth N., Lu S., Reck M., John T., Scherpereel A., De Marchi P., Aoyama T., Sathyanarayana P., Grootendorst D.J., Hu N., Ip V., Hung Y.H., Paz-Ares L.G. Nivolumab plus ipilimumab with chemotherapy as frst-line treatment of patients with metastatic non-small-cell lung cancer: fnal, 6-year outcomes from CheckMate 9LA. ESMO Open. 2025; 10(6): 105123. doi: 10.1016/j.esmoop.2025.105123.
Supplementary files
|
|
1. Fig. 1. Chest CT scan (October 18, 2022). S1 mass in the right lung. After 4 cycles of combination therapy with atezolizumab + bevacizumab + carboplatin + paclitaxel. In S1 of the lung, a lesion with radiant cord-like contours measuring 10×11×8 mm (previously 7×12×9 mm) is visualized. Note: created by the authors | |
| Subject | ||
| Type | Other | |
View
(217KB)
|
Indexing metadata ▾ | |
|
|
2. Fig. 2. Chest CT scan (October 18, 2022). A mass on the right scapula. After 4 cycles of combination therapy: atezolizumab + bevacizumab + carboplatin + paclitaxel. In the spine and upper third of the right scapula, a volumetric soft tissue lesion measuring 80×57×73 mm (previously 68×104×68 mm) is visualized. Note: created by the authors | |
| Subject | ||
| Type | Other | |
View
(191KB)
|
Indexing metadata ▾ | |
|
|
3. Fig. 3. Chest CT (September 22, 2025). A mass on the right scapula. After 54 cycles of maintenance therapy with atezolizumab and bevacizumab. In the spine and upper third of the body of the right scapula, a volumetric lesion of heterogeneous structure with signs of “swelling” remains, with destruction of bone tissue, with a soft tissue component spreading into the surrounding soft tissues, unevenly moderately accumulating contrast, with axial dimensions of 69×53 mm, with the presence of an osteoblastic component. Note: created by the authors | |
| Subject | ||
| Type | Other | |
View
(163KB)
|
Indexing metadata ▾ | |
Review
For citations:
Isaeva G.K., Sarycheva M.M., Vazhenin A.V., Dubinina A.V., Sheveleva K.M., Makruta I.V. Effcacy of combination of immunotherapy and chemotherapy as frst-line treatment for disseminated non-small cell lung cancer: a case report. Siberian journal of oncology. 2026;25(1):186-191. (In Russ.) https://doi.org/10.21294/1814-4861-2026-25-1-186-191
Views:
173
JATS XML
Email this article 
